The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10522 malaria professionals are enjoying the free benefits of MalariaWorld today

vaccine

NOT Open Access | Virus-like particles expressing Plasmodium berghei MSP-8 induce protection against P. berghei infection

August 5, 2020 - 14:10 -- NOT Open Access
Author(s): 
Lee SH, Chu KB, Kang HJ, Basak S, Kim MJ, Park H, Jin H, Moon EK, Quan FS
Reference: 
Parasite Immunol. 2020 Aug 1:e12781

Merozoite surface protein 8 (MSP‐8) of Plasmodium parasites play an important role in erythrocyte invasion and is a potential malaria vaccine candidate.

Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins

July 27, 2020 - 15:01 -- Open Access
Author(s): 
Singh K, Burkhardt M, Narum DL, et al.
Reference: 
Commun Biol. 2020 Jul 24;3(1):395

Proteins Pfs230 and Pfs48/45 are Plasmodium falciparum transmission-blocking (TB) vaccine candidates that form a membrane-bound protein complex on gametes. The biological role of Pfs230 or the Pfs230-Pfs48/45 complex remains poorly understood. Here, we present the crystal structure of recombinant Pfs230 domain 1 (Pfs230D1M), a 6-cysteine domain, in complex with the Fab fragment of a TB monoclonal antibody (mAb) 4F12. We observed the arrangement of Pfs230 on the surface of macrogametes differed from that on microgametes, and that Pfs230, with no known membrane anchor, may exist on the membrane surface in the absence of Pfs48/45.

Commentary in reply to a publication on Plasmodium falciparum pre-erythrocytic stage vaccine development

July 21, 2020 - 15:32 -- Open Access
Author(s): 
François P. Roman, Margherita Coccia and Lode Schuerman
Reference: 
Malaria Journal 2020 19:261, 20 July 2020

We have read the publication of Molina-Franky and colleagues on Plasmodium falciparum pre-erythrocytic stage vaccine development (Malaria Journal, 2020;19:56).

Bliss' and Loewe's additive and synergistic effects in Plasmodium falciparum growth inhibition by AMA1-RON2L, RH5, RIPR and CyRPA antibody combinations

July 20, 2020 - 15:35 -- Open Access
Author(s): 
Azasi Y, Gallagher SK, Diouf A, Dabbs RA, Jin J, Mian SY, Narum DL, Long CA, Gaur D, Draper SJ, Fay MP, Miller LH, Miura K
Reference: 
Sci Rep. 2020 Jul 16; 10(1):11802

Plasmodium invasion of red blood cells involves malaria proteins, such as reticulocyte-binding protein homolog 5 (RH5), RH5 interacting protein (RIPR), cysteine-rich protective antigen (CyRPA), apical membrane antigen 1 (AMA1) and rhoptry neck protein 2 (RON2), all of which are blood-stage malaria vaccine candidates. So far, vaccines containing AMA1 alone have been unsuccessful in clinical trials.

NOT Open Access | Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults

May 13, 2020 - 13:57 -- NOT Open Access
Author(s): 
Nouatin O, Ateba Ngoa U, Adegnika AA, et al.
Reference: 
Vaccine. 2020 May 5. pii: S0264-410X(20)30540-5

Despite appreciable immunogenicity in malaria-naive populations, many candidate malaria vaccines are considerably less immunogenic in malaria-exposed populations. This could reflect induction of immune regulatory mechanisms involving Human Leukocyte Antigen G (HLA-G), regulatory T (Treg), and regulatory B (Breg) cells. Here, we addressed the question whether there is correlation between these immune regulatory pathways and both plasmablast frequencies and vaccine-specific IgG concentrations.

A novel vaccine target for malaria

May 13, 2020 - 13:46 -- Open Access
Author(s): 
Wrighton KH
Reference: 
Nat Rev Microbiol. 2020 May 6

Malaria is a leading cause of death in children; however, developing an effective vaccine has been challenging. Raj et al. now show that Plasmodium falciparum glutamic-acid-rich protein (PfGARP), an 80 kDa antigen expressed on the surface of erythrocytes infected by P. falciparum, is a malaria vaccine candidate for specifically targeting the blood stage of P. falciparum.

The RH5-CyRPA-Ripr Complex as a Malaria Vaccine Target

May 5, 2020 - 13:09 -- Open Access
Author(s): 
Ragotte RJ, Higgins MK, Draper SJ
Reference: 
Trends Parasitol. 2020 Apr 28. pii: S1471-4922(20)30099-4

Despite ongoing efforts, a highly effective vaccine against Plasmodium falciparum remains elusive. Vaccines targeting the pre-erythrocytic stages of the P. falciparum life cycle are the most advanced to date, affording moderate levels of efficacy in field trials.

Pages

Subscribe to RSS - vaccine